Skip to main content
U.K. Edition
Thursday, 2 May 2024

Coronavirus may attack the brain and nervous system

Credit: Reuters - 3D Animations (Next Me
Duration: 01:33s 0 shares 1 views

Coronavirus may attack the brain and nervous system
Coronavirus may attack the brain and nervous system

A study of COVID-19 patients in Wuhan, China found coronavirus could lead to serious neurological complications in perhaps as many as one third of all patients, according to research published in the journal JAMA Neurology.

For story suggestions or custom animation requests, contact tips@nextanimation.com.tw.

Visit http://archive.nextanimationstudio.com to view News Direct's complete archive of 3D news animations.

RESTRICTIONS: Broadcast: NO USE JAPAN, NO USE TAIWAN Digital: NO USE JAPAN, NO USE TAIWAN A study of COVID-19 patients in the Chinese city of Wuhan, from where the pandemic originated, found coronavirus could lead to serious neurological complications in perhaps as many as one third of all patients.

In the study of 214 hospitalized COVID-19 patients in Wuhan published in the journal JAMA Neurology on April 10, researchers reported more than 35 percent had neurological complications, including decreased levels of cognition, stroke, and muscle damage.

Separately, France's National Union of Dermatologists-Venereologists, or SNDV, said in an April 6 press release that certain skin dermatological conditions may possibly be associated with Covid-19 infection.

RUNDOWN SHOWS: 1.

Wuhan, China on a map 2.

Neurological complications in COVID-19 patients in Wuhan study 3.

36.4 of patients in study had neurologic symptoms, while 45.5 percent of those with severe infections showed neurologic manifestations 4.

Common manifestations of COVID-19 5.

Reports indicate COVID-10 patients may experience anosmia, hyposmia, and dysgeusia 6.

France on a map 7.

Possible dermatological symptoms of COVID-1 include pseudo-frostbite, hives, and redness VOICEOVER (in English): "A study of COVID-19 patients in the Chinese city of Wuhan, from where the pandemic originated, found coronavirus could lead to serious neurological complications in perhaps as many as one third of all patients." "In the study of 214 hospitalized COVID-19 patients in Wuhan, researchers reported more than 35 percent had neurological complications, including decreased levels of cognition, stroke, and muscle damage." "Their findings, published in the journal JAMA Neurology on April 10, found 36.4 percent of those studied had neurologic symptoms. Among patients with more severe infections, 45.5 percent showed neurologic manifestations." "Not all patients with these symptoms exhibited common manifestations of the disease, namely a sore throat, dry cough, and diarrhea." "The news comes after previous reports that many COVID-10 patients experience anosmia, or the loss of smell; hyposmia, a reduced sense of smell; and dysgeusia, the distortion of the sense of taste." "These reported symptoms may indicate other ways in which the coronavirus could affect the brain." "Separately, France's National Union of Dermatologists-Venereologists, or SNDV, has reported that certain skin dermatological conditions may possibly be associated with Covid-19 infection." "In an April 6 press release, the organization said these symptoms include appearance of pseudo-frostbite of the extremities, transient hives, and sudden onset of persistent, sometimes painful redness." SOURCES: JAMA Neurology, Le Syndicat national des dermatologues-venereologues, American Academy of Otolaryngology-Head and Neck Surgery, ENT UK https://jamanetwork.com/journals/jamaneurology/fullarticle/2764549 https://www.syndicatdermatos.org/communique/communique-de-presse-06-04-20-covid19-et-peau/ https://www.entnet.org/content/aao-hns-anosmia-hyposmia-and-dysgeusia-symptoms-coronavirus-disease https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf *** For story suggestions please contact tips@nextanimation.com.tw For technical and editorial support, please contact: Asia: +61 2 93 73 1841 Europe: +44 20 7542 7599 Americas and Latam: +1 800 738 8377

You might like

Related news coverage

Advertisement